These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 22273579)
1. ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic. Rintoul JL; Lemay CG; Tai LH; Stanford MM; Falls TJ; de Souza CT; Bridle BW; Daneshmand M; Ohashi PS; Wan Y; Lichty BD; Mercer AA; Auer RC; Atkins HL; Bell JC Mol Ther; 2012 Jun; 20(6):1148-57. PubMed ID: 22273579 [TBL] [Abstract][Full Text] [Related]
2. Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer. van Vloten JP; Matuszewska K; Minow MAA; Minott JA; Santry LA; Pereira M; Stegelmeier AA; McAusland TM; Klafuric EM; Karimi K; Colasanti J; McFadden DG; Petrik JJ; Bridle BW; Wootton SK J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296558 [TBL] [Abstract][Full Text] [Related]
3. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493 [TBL] [Abstract][Full Text] [Related]
4. Identification of in vitro and in vivo oncolytic effect in colorectal cancer cells by Orf virus strain NA1/11. Chen D; Wang R; Long M; Li W; Xiao B; Deng H; Weng K; Gong D; Liu F; Luo S; Hao W Oncol Rep; 2021 Feb; 45(2):535-546. PubMed ID: 33416161 [TBL] [Abstract][Full Text] [Related]
5. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers. Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886 [TBL] [Abstract][Full Text] [Related]
6. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9. Deng L; Fan J; Guo M; Huang B Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055 [TBL] [Abstract][Full Text] [Related]
7. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model. Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398 [TBL] [Abstract][Full Text] [Related]
8. Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. Ricca JM; Oseledchyk A; Walther T; Liu C; Mangarin L; Merghoub T; Wolchok JD; Zamarin D Mol Ther; 2018 Apr; 26(4):1008-1019. PubMed ID: 29478729 [TBL] [Abstract][Full Text] [Related]
9. Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus. Ilett E; Kottke T; Donnelly O; Thompson J; Willmon C; Diaz R; Zaidi S; Coffey M; Selby P; Harrington K; Pandha H; Melcher A; Vile R Mol Ther; 2014 Oct; 22(10):1851-63. PubMed ID: 24957982 [TBL] [Abstract][Full Text] [Related]
10. Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Workenhe ST; Simmons G; Pol JG; Lichty BD; Halford WP; Mossman KL Mol Ther; 2014 Jan; 22(1):123-31. PubMed ID: 24343053 [TBL] [Abstract][Full Text] [Related]
11. Preclinical Safety Evaluation of Oncolytic Herpes Simplex Virus Type 2. Wang Y; Zhou X; Wu Z; Hu H; Jin J; Hu Y; Dong Y; Zou J; Mao Z; Shi X; Huo Y; Lyu J; Fang Z; Zhang W; Zhu Y; Li B; Liu B Hum Gene Ther; 2019 May; 30(5):651-660. PubMed ID: 30499341 [TBL] [Abstract][Full Text] [Related]
12. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Galivo F; Diaz RM; Wongthida P; Thompson J; Kottke T; Barber G; Melcher A; Vile R Gene Ther; 2010 Feb; 17(2):158-70. PubMed ID: 20016540 [TBL] [Abstract][Full Text] [Related]
13. Orf virus: A promising new therapeutic agent. Wang R; Wang Y; Liu F; Luo S Rev Med Virol; 2019 Jan; 29(1):e2013. PubMed ID: 30370570 [TBL] [Abstract][Full Text] [Related]
14. Preclinical efficacy and involvement of mTOR signaling in the mechanism of Orf virus against nasopharyngeal carcinoma cells. Huang Y; Gong K; Chen J; Deng H; Weng K; Wu H; Li K; Xiao B; Luo S; Hao W Life Sci; 2022 Feb; 291():120297. PubMed ID: 35007565 [TBL] [Abstract][Full Text] [Related]
16. IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity. Yang M; Giehl E; Feng C; Feist M; Chen H; Dai E; Liu Z; Ma C; Ravindranathan R; Bartlett DL; Lu B; Guo ZS Cancer Immunol Immunother; 2021 Sep; 70(9):2467-2481. PubMed ID: 33538860 [TBL] [Abstract][Full Text] [Related]